You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 4,255,415

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 4,255,415

Title:	Polyvinyl alcohol ophthalmic gel
Abstract:	An ophthalmic gel having an improved intensity and duration of the biological response is provided by utilizing a polyvinyl alcohol-sodium borate gel buffered to a pH of 6.5-8.5.
Inventor(s):	Chrai; Sukhbir S. (Belleville, NJ), Gupta; Santosh (Bloomfield, NJ), Hensley; Michael J. (Dover, NJ)
Assignee:	Schering Corporation (Kenilworth, NJ)
Application Number:	05/962,812
Patent Claims:	1. A topical ophthalmic gel comprising: 0.05-10% by weight of an ophthalmic medicament; 1-3% by weight of a polyvinyl alcohol of the grades 20-100, with a molecular weight of over 10,000, and a viscosity rating of 5-65; 0.1-1% by weight of a borate gelling agent, said borate gelling agent being an alkali metal or alkaline-earth borate salt or being generated in situ by the reaction of boric acid with aqueous alkali; and 8- 99% sterile water; said gel being maintained at a pH of 6.5-8.5. 2. A gel according to claim 1 wherein the ophthalmic medicament is pilocarpine hydrochloride. 3. A gel according to claim 1 wherein the ophthalmic medicament is pilocarpine nitrate. 4. A gel according to claim 1 wherein the ophthalmic medicament is gentamicin sulfate. 5. A gel according to claim 1 wherein the ophthalmic medicament is flunixin N-methyl glucamine. 6. A gel according to claim 1 wherein the ophthalmic medicament is betamethasone phosphate. 7. A gel according to claim 1 wherein the ophthalmic medicament is dexamethasone phosphate. 8. A gel according to claim 1 wherein the borate gelling agent is sodium borate. 9. A gel according to claim 1 wherein the borate gelling agent is generated in situ by boric acid and sodium hydroxide. 10. A gel according to claim 1 wherein the pH is about 7.4. 11. In a method of treating an ophthalmic ailment the improvement which comprises administering topically 0.05 to 0.8 ml of a therapeutic gel according to claim 1, 1-3 times a day. 12. A method according to claim 11 wherein the ophthalmic medicament is pilocarpine hydrochloride. 13. A method according to claim 11 wherein the ophthalmic medicament is pilocarpine nitrate. 14. A method according to claim 11 wherein the ophthalmic medicament is gentamicin sulfate. 15. A method according to claim 11 wherein the ophthalmic medicament is flunixin N-methyl glucamine. 16. A method according to claim 11 wherein the ophthalmic medicament is betamethasone phosphate. 17. A gel according to any of claims 1-7, wherein the ophthalmic medicament is present in an amount of 0.2-0.5 percent by weight. 18. A gel according to claim 17, wherein the pH is 7.0-8.5. 19. A gel according to claim 1, wherein the ophthalmic medicament is gentamicin sulfate and and pH is 7.0-8.5.

Details for Patent 4,255,415

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006	⤷ Try a Trial	2039-09-23
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.